Stock Events

Stock Events

Tempest Therapeutics 

€0
117
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1AprExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-3.73
-2.67
-1.6
-0.54
Expected EPS
-0.535866
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-79.5MNet Income

Analyst Ratings

$8.35Average Price Target
The highest estimate is 8.35.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3OS0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Tempest Therapeutics' oncology focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Tempest Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its strong presence in the oncology sector, competing with Tempest Therapeutics in developing cancer therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in direct competition with Tempest Therapeutics.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a multinational pharmaceutical company with a significant focus on oncology, competing in the same market as Tempest Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a major player in the oncology market, with a wide range of cancer treatments that compete with Tempest Therapeutics.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong oncology portfolio, making it a key competitor in the cancer therapy market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops cancer drugs, competing with Tempest Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is involved in developing treatments for cancer, among other diseases, competing in the oncology space with Tempest Therapeutics.

About

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Show more...
CEO
ISIN
US87978U2078
WKN
000A41556

Listings

F
DE
3OS0.F
XNAS
US
TPST
BOATS
BOATS
TPST.BOATS

0 Comments

Share your thoughts

FAQ

What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tempest Therapeutics stocks are traded under the ticker 3OS0.F.
Is Tempest Therapeutics stock price growing?▼
3OS0.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Tempest Therapeutics has showed a -35.13% decrease.
What is Tempest Therapeutics revenue for the last year?▼
Tempest Therapeutics revenue for the last year amounts to 0 EUR.
What is Tempest Therapeutics net income for the last year?▼
3OS0.F net income for the last year is -79.5M EUR.
When did Tempest Therapeutics complete a stock split?▼
The last stock split for Tempest Therapeutics was on January 30, 2026 with a ratio of 2:1.